Key points from article :
Neurotrack, a leader in cognitive health innovation, has introduced a groundbreaking three-minute digital cognitive screening test. Designed for integration into primary care settings, the tool allows healthcare providers or patients themselves to quickly and accurately identify early signs of cognitive impairment, such as dementia or Alzheimer's. Unlike traditional methods, the test uses culturally-neutral symbols and numbers to minimize bias, making it accessible to diverse populations.
Despite Medicare guidelines requiring cognitive assessments during annual wellness visits, most eligible individuals report not receiving these evaluations. Neurotrack aims to change this by positioning its test as a “new vital sign” for patients aged 65 and older. Early detection could lead to more effective interventions, addressing changes in the brain that often begin decades before symptoms appear.
Neurotrack is also working on digital therapeutics to prevent or delay cognitive decline in patients flagged by its tool. In collaboration with the University of Arkansas and funded by the National Institute on Aging, the company’s ongoing research shows promising results, with participants experiencing improvements in memory and reductions in depression and anxiety after a year of health coaching.
Backed by $10 million in new funding, Neurotrack plans to accelerate its rollout across the U.S., develop further provider-based solutions, and engage healthcare leaders through a new clinical advisory board. The initiative reflects a growing urgency to address cognitive health in ageing populations, particularly in the wake of pandemic-driven social isolation, which has exacerbated risks of cognitive decline.
